期刊
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
卷 21, 期 4, 页码 763-770出版社
BMJ PUBLISHING GROUP
DOI: 10.1097/IGC.0b013e31821b2669
关键词
Molecular agents; Ovarian cancer; Clinical trials
资金
- Astra Zeneca
- Roche
- GlaxoSmithKline
- Pharmamar
- Ortho Biotech
- Boehringer Ingelheim
- Canadian Cancer Society Research Institute
- Ovarian Cancer Canada
- National Cancer Institute (US)
- Taiho
- Merck
- Pfizer
- Amgen
- MRC [G0601891] Funding Source: UKRI
- Medical Research Council [G0601891] Funding Source: researchfish
There is now a greater understanding of the molecular pathways in ovarian cancer, and using this knowledge, a large number of new therapeutic agents can be tested. The success of these drugs will depend on selecting drugs that target known key dysfunctional molecular pathways. To make best use of these compounds, prognostic and predictive biomarkers need to be identified. Novel methods of assessment such as functional imaging need to be developed as additional biological end points to evaluate these therapies. Promising antitumor activity has been observed with some drugs, and careful consideration is needed to determine in what circumstances new agents, such as anti-angiogenic compounds, could be considered as a standard therapy. These areas were discussed at the 4th Ovarian Cancer Consensus Conference.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据